Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Introduction: Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy. Several substituted coumarins have shown activity as inhibitors of monoamine oxidase B. Objec...
Published in: | Biomédica |
---|---|
Main Authors: | , , , , |
Format: | Article in Journal/Newspaper |
Language: | English Spanish |
Published: |
Instituto Nacional de Salud
2019
|
Subjects: | |
Online Access: | https://doi.org/10.7705/biomedica.4299 https://doaj.org/article/0bef9087aca8453f9c128e138c34846b |
id |
ftdoajarticles:oai:doaj.org/article:0bef9087aca8453f9c128e138c34846b |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:0bef9087aca8453f9c128e138c34846b 2023-05-15T15:08:18+02:00 Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent María del Pilar Olaya Nadezdha Esperanza Vergel José Luis López María Dolores Viña Mario Francisco Guerrero 2019-09-01T00:00:00Z https://doi.org/10.7705/biomedica.4299 https://doaj.org/article/0bef9087aca8453f9c128e138c34846b EN ES eng spa Instituto Nacional de Salud https://revistabiomedica.org/index.php/biomedica/article/view/4299 https://doaj.org/toc/0120-4157 0120-4157 doi:10.7705/biomedica.4299 https://doaj.org/article/0bef9087aca8453f9c128e138c34846b Biomédica: revista del Instituto Nacional de Salud, Vol 39, Iss 3, Pp 491-501 (2019) Parkinson’s disease monoamine oxidase coumarins models animal reserpine levodopa haloperidol antioxidants Medicine R Arctic medicine. Tropical medicine RC955-962 article 2019 ftdoajarticles https://doi.org/10.7705/biomedica.4299 2022-12-31T00:47:09Z Introduction: Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy. Several substituted coumarins have shown activity as inhibitors of monoamine oxidase B. Objective: To evaluate the possible antiparkinsonian effects of the coumarin analogue FCS005 (3-methyl-7H-furo[3,2-g]chromen-7-one) in mouse models, as well as its inhibitory activity towards monoamine oxidases (MAO) and its antioxidant activity. Materials and methods: FCS005 was synthesized and the reversal of hypokinesia was evaluated in the reserpine and levodopa models. Moreover, in the haloperidol model, its anticataleptic effects were evaluated. Additionally, the monoamine oxidase inhibitory activity and antioxidant activity of FCS005 were evaluated using in vitro and ex vivo studies, respectively. Results: FCS005 (100 mg/kg) caused the reversal of hypokinesia in the reserpine and levodopa models. This furocoumarin also presented anti-cataleptic effects at the same dose. Besides, it showed selective inhibitory activity towards the MAO-B isoform and antioxidant activity. Conclusion: These results attribute interesting properties to the compound FCS005. It is important to continue research on this molecule considering that it could be a potential antiparkinsonian agent. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Biomédica 39 3 491 501 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English Spanish |
topic |
Parkinson’s disease monoamine oxidase coumarins models animal reserpine levodopa haloperidol antioxidants Medicine R Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
Parkinson’s disease monoamine oxidase coumarins models animal reserpine levodopa haloperidol antioxidants Medicine R Arctic medicine. Tropical medicine RC955-962 María del Pilar Olaya Nadezdha Esperanza Vergel José Luis López María Dolores Viña Mario Francisco Guerrero Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent |
topic_facet |
Parkinson’s disease monoamine oxidase coumarins models animal reserpine levodopa haloperidol antioxidants Medicine R Arctic medicine. Tropical medicine RC955-962 |
description |
Introduction: Parkinson’s disease is the second most common neurodegenerative disease. Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy. Several substituted coumarins have shown activity as inhibitors of monoamine oxidase B. Objective: To evaluate the possible antiparkinsonian effects of the coumarin analogue FCS005 (3-methyl-7H-furo[3,2-g]chromen-7-one) in mouse models, as well as its inhibitory activity towards monoamine oxidases (MAO) and its antioxidant activity. Materials and methods: FCS005 was synthesized and the reversal of hypokinesia was evaluated in the reserpine and levodopa models. Moreover, in the haloperidol model, its anticataleptic effects were evaluated. Additionally, the monoamine oxidase inhibitory activity and antioxidant activity of FCS005 were evaluated using in vitro and ex vivo studies, respectively. Results: FCS005 (100 mg/kg) caused the reversal of hypokinesia in the reserpine and levodopa models. This furocoumarin also presented anti-cataleptic effects at the same dose. Besides, it showed selective inhibitory activity towards the MAO-B isoform and antioxidant activity. Conclusion: These results attribute interesting properties to the compound FCS005. It is important to continue research on this molecule considering that it could be a potential antiparkinsonian agent. |
format |
Article in Journal/Newspaper |
author |
María del Pilar Olaya Nadezdha Esperanza Vergel José Luis López María Dolores Viña Mario Francisco Guerrero |
author_facet |
María del Pilar Olaya Nadezdha Esperanza Vergel José Luis López María Dolores Viña Mario Francisco Guerrero |
author_sort |
María del Pilar Olaya |
title |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent |
title_short |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent |
title_full |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent |
title_fullStr |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent |
title_full_unstemmed |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent |
title_sort |
coumarin analogue 3-methyl-7h-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent |
publisher |
Instituto Nacional de Salud |
publishDate |
2019 |
url |
https://doi.org/10.7705/biomedica.4299 https://doaj.org/article/0bef9087aca8453f9c128e138c34846b |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Biomédica: revista del Instituto Nacional de Salud, Vol 39, Iss 3, Pp 491-501 (2019) |
op_relation |
https://revistabiomedica.org/index.php/biomedica/article/view/4299 https://doaj.org/toc/0120-4157 0120-4157 doi:10.7705/biomedica.4299 https://doaj.org/article/0bef9087aca8453f9c128e138c34846b |
op_doi |
https://doi.org/10.7705/biomedica.4299 |
container_title |
Biomédica |
container_volume |
39 |
container_issue |
3 |
container_start_page |
491 |
op_container_end_page |
501 |
_version_ |
1766339690945839104 |